Clinical Trials Logo
  1. Home
  2. Cushing Disease
  3. NCT00171951

Extension Study to Assess the Safety and Efficacy of Pasireotide in Participants With Cushing's Disease

Cushing Disease Clinical Trial

Official title:
Extension to a Multicenter, Open-label Study to Assess the Safety and Efficacy of 600 μg SOM230, Administered Subcutaneously, Bid in Patients With Cushing's Disease

Clinical Trial Summary

Cushing's disease is a rare serious condition that is caused by an adrenocorticotropic hormone (ACTH) secreting pituitary adenoma. This study assessed the long-term safety and efficacy of pasireotide in participants with Cushing's disease.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT00171951
Study type Interventional
Source Novartis
Contact
Status Completed
Phase Phase 2
Start date August 13, 2004
Completion date July 8, 2013
View Details
See also
  Status Clinical Trial Phase
Completed NCT02350153 - Cushing´s Disease Epidemiology in Sweden
Not yet recruiting NCT03297892 - Health Status of the Patients Followed for a Disease of Cushing in the Region Large-West of 1990 to 2015 N/A
Recruiting NCT05804669 - A Study to Evaluate the Safety and PK of CRN04894 for the Treatment of Cushing's Syndrome Phase 1/Phase 2
Recruiting NCT03364803 - Collecting Information About Treatment Results for Patients With Cushing's Syndrome
Recruiting NCT03774446 - Multicenter Study of Seliciclib (R-roscovitine) for Cushing Disease Phase 2
Completed NCT03080181 - Adipokine Profile in Patients With Cushing's Disease on Pasireotide Treatment Phase 4
Recruiting NCT03831958 - Long-Term Follow-Up of Survivors of Pediatric Cushing Disease
Completed NCT01331239 - Safety and Efficacy of LCI699 in Cushing's Disease Patients Phase 2
Completed NCT04201444 - Hair Cortisol and Cushing's Disease N/A
Completed NCT02233335 - The Factors Associated With the Recurrence in Patients With Cushing Disease N/A
Recruiting NCT04374721 - Clinical Study on Circadian Genes Dysregulation in Patients With Glucocorticoid Disorders N/A
Recruiting NCT03974789 - Discriminant Capacity and Thresholds of Salivary Cortisol in Chemiluminescence in the Diagnosis of Hypercorticisms
Completed NCT03621280 - Open-label Treatment in Cushing's Syndrome Phase 3
Not yet recruiting NCT05971758 - Fimepinostat, Combination HDAC and Pi3-kinase Inhibitor Tumor-Directed Therapy for Cushing Disease Phase 2
Recruiting NCT04486859 - Postoperative Thrombosis Prevention in Patients With CD N/A
Recruiting NCT00001595 - An Investigation of Pituitary Tumors and Related Hypothalmic Disorders